Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Margetuximab in HER2 2+ advanced breast cancer
NCT01828021Phase 2Completed
- Sponsor
- MacroGenics
- Start
- Mar 2013
- Primary completion
- Dec 2016
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of margetuximab in breast cancer, sponsored by MacroGenics. Primary endpoint: Best Overall Response. Started Mar 2013; status: completed.
02
Drugs
margetuximab
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT01828021.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01828021.